News | February 03, 2011

CMS Expands Coverage for F-18 Sodium Fluoride PET Scans

February 3, 2011 – Beginning Feb. 7, 2011, the Centers for Medicare and Medicaid Services (CMS) will reimburse sites participating in the National Oncologic PET Registry (NOPR) for F-18 sodium fluoride (NaF) positron emission tomography (PET) scans.

Approximately 1.5 million patients are diagnosed with cancer each year in the United States. Many of these patients will develop metastases to bone during the course of their disease. Now, physicians treating Medicare patients with known or suspected cancer metastatic to bone can much more widely order PET scans using the NaF radiotracer to help formulate treatment plans.

The primary objective of the expanded NOPR is to assess the effect of NaF-PET on how physicians manage the care of their Medicare patients. The project seeks to answer questions about whether NaF-PET results in physicians changing patient care to more appropriate palliative or curative care.

Studies in the past decade have demonstrated that NaF-PET has a higher diagnostic accuracy than conventional bone scans with technetium-99m. It also has the advantage of significantly shorter scan times (approximately one hour for NaF-PET and three to four hours for a bone scan). However, these scans have not realized widespread use, in large part, because of a lack of insurance coverage – and most notably Medicare coverage.

In early 2010, CMS announced its conclusion that the evidence is not sufficient to determine NaF-PET improves health outcomes of beneficiaries with cancer. However, it also determined that the scan can be covered if it is performed through Coverage with Evidence Development (CED) that requires, as a condition of payment, collection of additional data to assess the scan’s impact on patient care.

A previous similar determination by CMS led to the NOPR’s establishment and subsequent participation of over 1,900 PET facilities, data collection on nearly 200,000 FDG-PET scans (as of Dec. 31, 2010) and CMS coverage for the vast majority of FDG-PET indications. The extensive experience of the NOPR investigators and staff, established processes and data collection infrastructure, and strong CMS collaboration led the same team to develop the NaF-PET component of the NOPR.

All PET facilities currently participating in the NOPR are eligible to participate in the expanded program, and new facilities are encouraged to join. Patient registrations will be accepted beginning at 9:00 a.m. EST on Feb. 7, 2011.

For more information: www.cancerPETregistry.org

Related Content

FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Therapixel Appoints Matthieu Leclerc-Chalvet as CEO
News | Artificial Intelligence | July 03, 2019
Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu...
Bracco Imaging Acquires Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers | July 01, 2019
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
Sectra Providing Centralized Regional Solution for Digital Pathology in the U.K.
News | Digital Pathology | June 14, 2019
Sectra has signed a five-year contract with North Tees and Hartlepool National Health System (NHS) Foundation Trust for...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...